What is Elafibranor-Iqirvo?

Elafibranor-Iqirvo is a dual peroxisome-activated receptor (PPAR) alpha/delta (alpha, delta) agonist indicated for the treatment of patients with primary biliary cholangitis. Iqirvo tablets are used in combination with ursodeoxycholic acid (UDCA) for the treatment of adults with primary cholangitis (PBC) who have poor response to UDCA or for the treatment of patients who cannot tolerate UDCA.

Primary cholangitis is a rare, progressive autoimmune cholestatic liver disease that causes a buildup of bile and toxins (cholestasis) and chronic inflammation that can lead to irreversible liver fibrosis (scarring) and bile duct destruction. Common symptoms include fatigue and itching, which in severe cases can affect quality of life. If left untreated, primary cholangitis can lead to liver failure or, in extreme cases, death. Iqirvo targets multiple cell types and biological processes involved in PBC pathophysiology by activating PPAR alpha, delta, including cholestasis (disorder of intrahepatic bile flow), bile toxicity, inflammation and fibrosis, and bile acid output.

Based on data from a phase III trial, Iqirvo received accelerated approval. The drug is an 80 mg tablet to be taken orally once daily. Iqirvo side effects may include weight gain, diarrhea, abdominal pain, nausea, vomiting, joint pain, constipation, muscle damage, bone fractures, gastroesophageal reflux disease, dry mouth, weight loss, and rash. These side effects affect 5% or more of patients.

In general,Iqirvo, as a new option for the treatment of PBC, provides hope for patients who are poor or intolerant to traditional treatments. However, during use, patients need to pay close attention to possible adverse reactions and follow the doctor's instructions for medication to obtain the best therapeutic effect.